

This document is an English translation of a statement written originally in Japanese. The Japanese original should be considered as the primary version.

Consolidated Financial Results for the Fiscal Year Ended May 31, 2025 (Japanese GAAP)

July 14, 2025

Name of Listed Company: CREATE SD HOLDINGS CO., LTD.

Listing: Tokyo Stock Exchange

Securities code: 3148

URL: https://www.createsdhd.co.jp/English/tabid/129/Default.aspx

Representative: Taizo Hirose, Representative Director and President

Contact: Tetsuya Yamazaki, Executive Officer and General Manager, Finance and

Tel: +81-45-914-8241

Accounting Dept.

Scheduled date of the Ordinary General Meeting of Shareholders:

August 22, 2025

Scheduled date of start of dividend payment:

August 25, 2025

Scheduled filing date of Securities Report: August 21, 2025 Supplementary materials for the financial results: Yes

Financial results briefing sessions: Yes (For securities analysts and institutional investors)

(Figures are rounded down to the nearest million yen)

1. Consolidated Results for Fiscal Year Ended May 31, 2025 (June 1, 2024 to May 31, 2025)

(1) Consolidated Operating Results

(Figures in percentages denote the year-on-year change)

<u> </u>	(-8 F F							
	Net sale	es .	Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Fiscal year ended May 31, 2025	457,093	8.2	22,625	11.9	23,414	12.1	15,685	14.6
Fiscal year ended May 31, 2024	422,330	10.9	20,227	7.0	20,882	7.5	13,691	5.9

(Note) Comprehensive income:

Fiscal year ended May 31, 2025: ¥15,868 million (13.6%) Fiscal year ended May 31, 2024: ¥13,967 million (6.5%)

	Earnings per share	Diluted earnings per share	Return on equity	Return on assets	Operating margin
	Yen	Yen	%	%	%
Fiscal year ended May 31, 2025	242.82	-	11.5	10.3	4.9
Fiscal year ended May 31, 2024	215.61	215.61	11.1	10.2	4.8

(Reference) Share of profit of entities accounted for using equity method:

Fiscal year ended May 31, 2025: ¥— million Fiscal year ended May 31, 2024: ¥— million

(2) Consolidated Financial Position

	Total assets	Total net assets	Equity ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
As of May 31, 2025	236,561	142,720	60.3	2,209.23
As of May 31, 2024	216,481	130,243	60.2	2,027.07

(Reference) Net assets: As of May 31, 2025: ¥142,720 million As of May 31, 2024: ¥130,224 million

(3) Consolidated Cash Flows

(5) Consolidated Cash Flows									
	Net cash provided by	Net cash used in investing	Net cash used in financing	Cash and cash equivalents					
	operating activities	activities	activities	at end of period					
	Millions of yen	Millions of yen	Millions of yen	Millions of yen					
Fiscal year ended May 31, 2025	23,625	(20,700)	(3,390)	37,346					
Fiscal year ended May 31, 2024	21,034	(20,207)	(140)	37,812					

2. Dividend Payments

_	Dividends per share					Total dividends	Dividend	Dividend on
	First quarter	Second quarter	Third quarter	Year-end	Annual	paid (annual)	payout ratio (consolidated)	equity ratio (consolidated)
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended May 31, 2024	_	27.00	_	37.00	64.00	4,083	29.7	3.3
Fiscal year ended May 31, 2025	_	34.00	1	44.00	78.00	5,038	32.1	3.7
Fiscal year ending May 31, 2026 (forecast)	_	45.00	_	45.00	90.00		35.7	

3. Consolidated Financial Forecast (From June 1, 2025 to May 31, 2026)

(Figures in percentages denote the year-on-year change)

	Net sales		Operating pro	ofit	Ordinary pro	fit	Profit attributat owners of par		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Six months ending November 30, 2025	240,700	7.1	11,260	7.6	11,660	7.9	7,900	12.5	122.29
Full-year	491,500	7.5	24,100	6.5	24,900	6.3	16,300	3.9	252.31

Notes

(1) Significant changes of subsidiaries in the fiscal year ended May 31, 2025: None

Newly consolidated: — companies (company name(s)); Deconsolidated: — companies (company name(s))

(2) Changes in accounting policies, changes of accounting estimates and restatement

(i) Changes in accounting policies due to amendments to accounting standards: Yes

(ii) Other changes in accounting policies: None

(iii) Changes in accounting estimates: None

(iv) Restatements: None

- (3) Issued shares (common shares)
 - (i) Issued shares (including treasury shares) at period-end:
 - (ii) Treasury shares at period-end:
 - (iii) Average issued shares during period:

Fiscal year ended May 31, 2025	66,819,342 shares	Fiscal year ended May 31, 2024	66,819,342 shares
Fiscal year ended May 31, 2025	2,217,058 shares	Fiscal year ended May 31, 2024	2,576,458 shares
Fiscal year ended May 31, 2025	64,595,671 shares	Fiscal year ended May 31, 2024	63,500,165 shares

Note on issued shares

(Reference) Overview of Non-Consolidated Results

1. Non-Consolidated Results for Fiscal Year Ended May 31, 2025 (June 1, 2024 to May 31, 2025)

(1) Non-Consolidated Operating Results

(Figures in percentages denote the year-on-year change)

	Net sale	es	Operating p	profit	Ordinary p	rofit	Profit attribut owners of p	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Fiscal year ended May 31, 2025	8,968	9.4	8,442	9.5	8,555	9.8	7,963	10.1
Fiscal year ended May 31, 2024	8,195	3.9	7,709	4.7	7,794	5.8	7,232	5.7

	Earnings per share	Diluted earnings per share
	Yen	Yen
Fiscal year ended May 31, 2025	123.29	_
Fiscal year ended May 31, 2024	113.90	113.90

(2) Non-Consolidated Financial Position

	Total assets	Total net assets	Equity ratio	Net assets per share	
	Millions of yen	Millions of yen	%	Yen	
As of May 31, 2025	65,951	65,181	98.8	1,008.96	
As of May 31, 2024	60,760	60,607	99.7	943.13	

(Reference) Net assets: As of May 31, 2025: ¥65,181 million As of May 31, 2024: ¥60,589 million

This financial summary is not subject to audits by certified public accountants or audit firms.

Cautionary statement regarding business results forecasts and special notes

The financial forecasts and other forward-looking statements contained herein are based on currently available information and certain assumptions considered by the Company to be reasonable. Actual financial results may differ materially due to various factors. Refer to "1. Operating Results (4) Future Outlook" on page 4 of the supplementary material for the underlying assumptions and proper use of the forecasts.

Contents

. Operating Results	2
(1) Operating Results for the Fiscal Year under Review	
(2) Financial Position	
(3) Cash Flows	
(4) Future Outlook	
Basic Concept of Selecting Accounting Standards	
Consolidated Financial Statements and Notes	
(1) Consolidated Balance Sheet	
(2) Consolidated Statements of Income and Comprehensive Income	
Consolidated Statement of Income	
Consolidated Statement of Comprehensive Income.	
(3) Consolidated Statements of Changes in Equity	
(4) Consolidated Statements of Cash Flows	
(5) Notes to Consolidated Financial Statements	13
Going concern assumption	13
Changes to accounting policies	13
Segment information	13
Per share information	13
Significant subsequent events	13
. Other	15
(1) Changes in Officers	15
(2) Other	

1. Operating Results

(1) Operating Results for the Fiscal Year under Review

During the fiscal year ended May 31, 2025 (June 1, 2024 to May 31, 2025), the Japanese economy showed a gradual recovery trend, supported by improvements in employment and income conditions, as well as an increase in the number of foreign visitors to Japan, signaling progress in the normalization of economic and social activities. However, uncertainties about the future persist due to concerns over a slowdown in personal consumption caused by ongoing price increases, heightened geopolitical risks, and fluctuations in financial and capital markets.

In the drug store industry, the environment surrounding the Company has become increasingly challenging due to the intensified competition from the opening of stores by competitors across different sectors and business models, heightened price competition, and the trend toward industry consolidation and scale expansion through M&A among major players.

Under these circumstances, the Group is promoting comprehensive health care support for regional contribution in the domains of daily life, prevention, medical care, and nursing care as we continue to strengthen our dominant position in existing areas, mainly in in-store prescription drug stores, to achieve the Medium-term Management Plan.

Drug Stores

The drug store business faced a further strengthening of the tendency among households to seek money savings and consume selectively. In response, we continued to promote our everyday low prices (EDLP) strategy offering affordable prices at all times, thus acting as a lifeline to support the health and lifestyles of local customers and patients. We also continued our efforts to realize quick, one-stop shopping by promoting in-store prescription drug stores and improving convenience and expertise in small trade areas by expanding the lineup of fresh foods and other food products.

During the fiscal year ended May 31, 2025, the merchandise sales division continued to see steady growth in both net sales and customer numbers at existing stores driven by the sustained promotion of our EDLP strategy. In addition to opening new stores in a variety of formats, we resumed openings of "Cremo" stores specializing in enhanced beauty care, developed new stores in clinic malls in collaboration with medical institutions, and worked to strengthen the competitiveness of existing stores through initiatives such as remodeling involving a review of merchandising and floor space expansion. In the prescriptions division, efforts focused on strengthening collaboration with nearby medical institutions and enhancing the calculation of various reimbursement additions. Additionally, the division worked on establishing a system to handle electronic prescriptions and expanding prescription counters, resulting in steady progress in the number of prescriptions handled and the average prescription unit price. On the cost management front, we actively pursued workforce control measures on-site, installed solar panels on store rooftops, and began operations at a new logistics center, with an emphasis not only on cost reduction but also on promoting environmentally responsible management.

During the period, we opened 40 new drug stores. On the other hand, we closed five stores, one for renovation works, two due to expiration of contracts, and two from the standpoint of improving management efficiency. In terms of prescription drug stores, we opened 37 new stores: 36 in-store prescription drug stores and one dedicated prescription drug store.

Nursing Care

Regarding the nursing care business, amid an aging population, we operate two paid assisted living facilities characterized by delicious meals for elderly people who want to live safely and securely under the care of nursing staff, as well as 37 half-day rehabilitative adult care centers for those who want to continue living at home. For our paid assisted living facilities and adult day care services we have put every effort into customer service, which is one of the distinctive characteristics of our Group, to increase user satisfaction and improve occupancy rates.

Owing to the efforts above, the number of Group stores as of May 31, 2025, was as follows: 787 drug stores, one supermarket, and five combination drug store/fresh produce stores. The total number of prescription drug stores was 455, consisting of 38 dedicated prescription drug stores and 417 in-store prescription drug stores. The Group also has two paid assisted living facilities and 37 half-day adult care centers in the nursing care business.

As a result of the above, the financial results for the fiscal year under review were as follows: Net sales came in at 457,093 million yen (up 8.2% year on year), operating profit was 22,625 million yen (up 11.9%), ordinary profit was 23,414 million yen

(up 12.1%), and profit attributable to owners of parent was 15,685 million yen (up 14.6%).

(2) Financial Position

Total assets were 236,561 million yen, up 20,079 million yen from the end of the previous fiscal year. The main factors were an increase of 2,080 million yen in accounts receivable - trade, 3,643 million yen in merchandise, and 15,229 million yen in non-current assets due to an increase in new and soon to be opened stores.

Total liabilities were 93,840 million yen, up 7,601 million yen from the end of the previous fiscal year. The main factors were an increase of 3,405 million yen in accounts payable - trade, 1,703 million yen in income taxes payable, and 228 million yen in long-term asset retirement obligations.

Net assets were 142,720 million yen, up 12,477 million yen from the end of the previous fiscal year. The main factors were a 4,573 million yen decrease due to dividends paid, an increase of 763 million yen in capital surplus due to exercise of share options, a decrease of 438 million yen in treasury shares, and the recording of 15,685 million yen in profit attributable to owners of parent.

(3) Cash Flows

Cash and cash equivalents at the end of the fiscal year under review totaled 37,346 million yen, down 465 million yen from the end of the previous fiscal year.

Cash flows for the fiscal year ended May 31, 2025 were as follows:

Cash flows from operating activities

Net cash provided by operating activities amounted to 23,625 million yen, up 2,590 million yen year on year. The main factors of the increase were profit before income taxes of 21,988 million yen, depreciation of 5,675 million yen, impairment losses of 950 million yen, and income tax refunds of 863 million yen, which offset cash outflows such as an increase in trade receivables of 2,080 million yen, an increase in inventories of 3,672 million yen, and income taxes paid of 5,930 million yen.

Cash flows from investing activities

Net cash used in investing activities amounted to 20,700 million yen, up 493 million yen year on year. This was mainly due to 17,524 million yen of purchase of property, plant and equipment associated with the store openings, 478 million yen of loan advances, and 3,413 million yen for store openings in progress.

Cash flows from financing activities

Net cash used in financing activities amounted to 3,390 million yen, up 3,249 million yen year on year. This is the result of dividends paid of 4,573 million yen and proceeds from disposal of treasury shares of 1,198 million yen.

Capital resources and liquidity of funds

Regarding the Group's capital resources and liquidity of funds, cash obtained mainly from operating activities are used for capital investment for the opening of new stores.

(4) Future Outlook

In the next fiscal year, the Japanese economy is expected to show a moderate recovery supported by improvements in the employment and income environment and an increase in the number of foreign visitors to Japan. However, the outlook is expected to remain uncertain due to concerns over a slowdown in personal consumption resulting from continued inflation, heightened geopolitical risks, and fluctuations in financial and capital markets.

The harsh business environment in the drug store industry is expected to continue as competition further intensifies across industries, M&A and industry reorganization moves heat up, as well as with the risk of downward pressure due to revisions to medical fees and drug prices.

Amid these conditions, the Group is currently formulating a new Medium-term Management Plan beginning in the fiscal year ending May 31, 2026, with details scheduled to be announced on July 17, 2025.

As part of our commitment to enhancing long-term corporate value, the new Medium-term Management Plan will focus on three key pillars: (1) Growth Strategy, (2) Financial Strategy, and (3) Promotion of Sustainability Management.

Under the growth strategy, the Group will work to expand its top line through organic growth by deepening its dominant position in existing areas, expanding into new store locations, promoting diverse store formats, enhancing the product lineup including fresh foods, and pursuing scrap-and-build redevelopment of existing stores, while also actively pursuing scale expansion through M&A.

Under the financial strategy, while maintaining financial soundness, we aim to clarify our cash allocation policy by balancing proactive growth investments for sustainable growth and enhanced shareholder returns. Through this approach, we will strive to improve management transparency and maximize corporate value.

In promoting sustainability management, we will advance initiatives in the areas of environment (E), society (S), and governance (G), with the goal of achieving both sustainable corporate value enhancement and the realization of a sustainable society.

Based on the above, we forecast the financial results for the fiscal year ending May 31, 2026 as follows:

Consolidated Financial Forecast (From June 1, 2025 to May 31, 2026)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent
Full-year	Millions of yen	Millions of yen	Millions of yen	Millions of yen
	491,500	24,100	24,900	16,300

(Reference) Forecast earnings per share: 252.31 yen, average number of shares during the forecast period: 64,602,284 shares (Note) The above forecasts, which include risks and uncertainties, are made by the Company based on information available at the time. Actual results may differ from these forecasts due to various factors.

2. Basic Concept of Selecting Accounting Standards

The Group presently intends to prepare consolidated financial statements based on Generally Accepted Accounting Principles in Japan (Japanese GAAP), taking into account the comparability of consolidated financial statements over the period and the comparability between companies.

Regarding the application of International Financial Reporting Standards (IFRS), we will take appropriate measures in consideration of domestic and overseas circumstances.

3. Consolidated Financial Statements and Notes

(1) Consolidated Balance Sheet

		(Millions of yen)
	FY2023 (As of May 31, 2024)	FY2024 (As of May 31, 2025)
Assets		
Current assets		
Cash and deposits	38,212	37,746
Accounts receivable - trade	15,431	17,512
Merchandise	42,015	45,659
Supplies	115	144
Other	11,415	10,978
Total current assets	107,191	112,041
Non-current assets		
Property, plant and equipment		
Buildings and structures	60,300	73,734
Accumulated depreciation	(23,806)	(26,761)
Buildings and structures, net	36,493	46,973
Land	27,274	33,034
Construction in progress	3,019	_
Other	29,582	32,440
Accumulated depreciation	(24,189)	(26,104)
Other, net	5,392	6,336
Total property, plant and equipment	72,180	86,344
Intangible fixed assets		·
Goodwill	372	294
Other	770	650
Total intangible assets	1,142	944
Investments and other assets		
Investment securities	182	175
Long-term loans receivable	10,024	10,324
Deferred tax assets	6,878	7,924
Leasehold and guarantee deposits	11,939	12,303
Other	7,002	6,562
Allowance for doubtful accounts	(60)	(60)
Total investments and other assets	35,967	37,231
Total non-current assets	109,290	124,520
Total assets	216,481	236,561

	FY2023 (As of May 31, 2024)	FY2024 (As of May 31, 2025)
Liabilities		
Current liabilities		
Accounts payable - trade	56,357	59,763
Contract liabilities	3,600	3,760
Accrued income taxes	3,444	5,148
Accrued bonuses	387	384
Provision for bonuses for directors (and other officers)	157	150
Provision for point card certificates	160	190
Asset retirement obligations	6	19
Provision for loss on store closings	36	_
Provision for losses on cancellation	-	132
Other	13,374	15,119
Total current liabilities	77,524	84,668
Non-current liabilities		
Net defined benefit liability	3,234	3,263
Asset retirement obligations	3,925	4,153
Provision for loss on subleasing	24	17
Provision for losses on cancellation	_	238
Other	1,529	1,497
Total non-current liabilities	8,714	9,171
Total liabilities	86,238	93,840
Net assets		
Equity capital		
Share capital	1,000	1,000
Capital surplus	2,945	3,709
Retained earnings	129,019	140,131
Treasury shares	(3,144)	(2,705)
Total shareholders' equity	129,821	142,134
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	39	50
Remeasurements of defined benefit plans	363	536
Total accumulated other comprehensive income	403	586
Share options	18	_
Total net assets	130,243	142,720
Liabilities and net assets	216,481	236,561

(2) Consolidated Statements of Income and Comprehensive Income

Consolidated Statement of Income

	FY2023 (From June 1, 2023 to May 31, 2024)	(Millions of yen) FY2024 (From June 1, 2024 to May 31, 2025)
Net sales	422,330	457,093
Cost of sales	312,143	337,873
Gross profit	110,187	119,220
Selling, general and administrative expenses	., .,	., .
Provision for point card certificates	160	190
Salaries and allowances	36,131	38,808
Provision of allowance for doubtful accounts	21	_
Provision for bonuses	387	762
Provision for directors' bonuses	153	146
Retirement benefit expenses	777	706
Depreciation and amortization	4,847	5,436
Land/office rent	17,385	18,312
Other	30,095	32,230
Total selling, general and administrative expenses	89,959	96,594
Operating profit	20,227	22,625
Non-operating profit	20,227	22,020
Interest income	85	123
Dividend income	1	12.
Gain on receipt of donated non-current assets	30	26
Rent income	364	544
Subsidy income	166	_
Other	186	353
Total non-operating income	835	1,049
Non-operating expenses		-,
Provision of allowance for doubtful accounts	1	,
Compensation expenses	5	
Rental expenses	163	254
Other	10	
Total non-operating expenses	180	260
Ordinary profit	20,882	23,414
Extraordinary profit	20,002	23,11
Subsidy income	73	20
Other	1	200
Total extraordinary income	74	210
Extraordinary losses	/т	210
Loss on sale of non-current assets	26	2
Impairment losses	1,284	950
Provision for loss on store closings	36	
Loss on retirement of non-current assets	165	1:
Loss on tax purpose reduction entry of non-current		
assets	73	208
Loss on valuation of investment securities	_	20
Provision for losses on cancellation losses		371
Other	18	67
Total extraordinary losses	1,604	1,635

(Millions of	yen)
--------------	------

		(Millions of yell)
	FY2023 (From June 1, 2023 to May 31, 2024)	FY2024 (From June 1, 2024 to May 31, 2025)
Profit before income taxes	19,352	21,988
Income taxes - current	6,250	7,433
Income taxes - deferred	(588)	(1,129)
Total income taxes	5,661	6,303
Profit	13,691	15,685
Profit attributable to non-controlling interests		
Profit attributable to owners of parent	13,691	15,685

		(Millions of yen)
	FY2023 (From June 1, 2023 to May 31, 2024)	FY2024 (From June 1, 2024 to May 31, 2025)
Profit	13,691	15,685
Other comprehensive income		
Valuation difference on available-for-sale securities	0	10
Remeasurements of defined benefit plans, net of tax	275	172
Total other comprehensive income	276	183
Comprehensive income:	13,967	15,868
Comprehensive income attributable to:		
Owners of parent	13,967	15,868
Non-controlling interests	_	_

(3) Consolidated Statements of Changes in Equity

FY2023 (June 1, 2023 to May 31, 2024)

(Millions of yen)

	Equity capital				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	1,000	934	118,741	(4,393)	116,282
Changes during period					
Dividends of surplus			(3,413)		(3,413)
Profit attributable to owners of parent			13,691		13,691
Purchase of treasury shares				(0)	(0)
Exercise of share options		2,011		1,249	3,261
Net changes in items other than shareholders' equity					
Total changes during period		2,011	10,277	1,249	13,538
Balance at end of period	1,000	2,945	129,019	(3,144)	129,821

	Accumul	lated other comprehensiv	re income		
	Valuation difference on available-for-sale securities	Remeasurements of defined benefit plans	Total accumulated other comprehensive income	Share options	Total net assets
Balance at beginning of period	39	87	126		116,409
Changes during period					
Dividends of surplus					(3,413)
Profit attributable to owners of parent					13,691
Purchase of treasury shares					(0)
Exercise of share options					3,261
Net changes in items other than shareholders' equity	0	275	276	18	295
Total changes during period	0	275	276	18	13,833
Balance at end of period	39	363	403	18	130,243

(Millions of yen)

	Equity capital				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	1,000	2,945	129,019	(3,144)	129,821
Changes during period					
Dividends of surplus			(4,573)		(4,573)
Profit attributable to owners of parent			15,685		15,685
Purchase of treasury shares					_
Exercise of share options		763		438	1,201
Net changes in items other than shareholders' equity					
Total changes during period	I	763	11,111	438	12,313
Balance at end of period	1,000	3,709	140,131	(2,705)	142,134

	Accumu	lated other comprehensiv	re income			
	Valuation difference on available-for-sale securities	Remeasurements of defined benefit plans	Total accumulated other comprehensive income	Share options	Total net assets	
Balance at beginning of period	39	363	403	18	130,243	
Changes during period						
Dividends of surplus					(4,573)	
Profit attributable to owners of parent					15,685	
Purchase of treasury shares					_	
Exercise of share options					1,201	
Net changes in items other than shareholders' equity	10	172	183	(18)	160	
Total changes during period	10	172	183	(18)	12,477	
Balance at end of period	50	536	586	_	142,720	

		(Millions of yen)
	FY2023 (From June 1, 2023 to May 31, 2024)	FY2024 (From June 1, 2024 to May 31, 2025)
Cash flows from operating activities	to May 31, 2024)	to May 31, 2023)
Profit before income taxes	19,352	21,988
	4,995	5,675
Depreciation and amortization		950
Impairment losses	1,284	
Increase (decrease) in allowance for doubtful accounts	19	(0)
Increase (decrease) in provision for bonuses Increase (decrease) in provision for bonuses for	8	(3)
directors (and other officers) Increase (decrease) in provision for point card	12	(7)
certificates	(10)	29
Increase (decrease) in provision for loss on subleasing	(6)	(6)
Increase (decrease) in provision for losses on cancellation	_	371
Increase (decrease) in provision for loss on store closings	36	_
Increase (decrease) in retirement benefit liability	322	281
Interest and dividend income	(87)	(124)
Decrease (increase) in trade receivables	(2,118)	(2,080)
Decrease (increase) in inventories	(3,578)	(3,672)
Increase (decrease) in trade payables	5,872	3,405
Increase (decrease) in advances received	240	(17)
Other	924	1,872
Subtotal	27,268	28,663
Interest and dividends received	3	28
Income taxes paid	(7,074)	(5,930)
Income taxes refund	837	863
Net cash provided by operating activities	21,034	23,625
Cash flows from investing activities	21,034	23,023
Purchase of property, plant and equipment	(15 772)	(17,524)
Purchase of intangible assets	(15,772)	
	(45)	(129)
Long-term loan advances Proceeds from collection of long-term loans receivable	(792) 1,076	(478) 1,094
Proceeds from sale of investment securities	2	3
Purchase of long-term prepaid expenses	(338)	(210)
Payments of leasehold and guarantee deposits	(233)	(152)
Proceeds from refund of leasehold and guarantee deposits	177	125
Payments for store openings in progress	(3,960)	(3,413)
Payments into deposit money	(310)	(9)
Other	(10)	(6)
Net cash used in investing activities	(20,207)	(20,700)
Cash flows from financing activities	(=0,=07)	(20,700)
Dividends paid	(3,413)	(4,573)
Purchase of treasury shares	(0)	(1,575)
Proceeds from disposal of treasury shares	3,250	1,198
Other	22	(15)
Net cash used in financing activities		(3,390)
_	(140)	
Net increase (decrease) in cash and cash equivalents	686	(465)
Cash and cash equivalents at beginning of period	37,126	37,812
Cash and cash equivalents at end of period	37,812	37,346

(5) Notes to Consolidated Financial Statements

Going concern assumption

Not applicable

Changes to accounting policies

Application of accounting standard for current income taxes, etc.

The Accounting Standard for Current Income Taxes, etc. (Accounting Standard No. 27, issued on October 28, 2022) has been applied from the beginning of the first quarter of the fiscal year ending May 31, 2026.

There is no impact on the consolidated financial statements as a result of this application.

Segment information

Since the Group has a high proportion of drug store business which is considered to be of little importance as disclosed information, segment information has been omitted.

Per share information

	FY2023 (From June 1, 2023 to May 31, 2024)	FY2024 (From June 1, 2024 to May 31, 2025)
Net assets per share	¥2,027.07	¥2,209.23
Earnings per share	¥215.61	¥242.82
Diluted earnings per share	¥215.61	_

Notes:

- 1. Diluted earnings per share not stated for the fiscal year under review because there were no diluted shares.
- 2. The basis for calculating earnings per share is as follows:

	FY2023 (From June 1, 2023 to May 31, 2024)	FY2024 (From June 1, 2024 to May 31, 2025)
Earnings per share		
Profit attributable to owners of parent (millions of yen)	13,691	15,685
Amount not attributable to ordinary shareholders (millions of yen)	_	_
Profit attributable to owners of parent related to common shares (millions of yen)	13,691	15,685
Average number of common shares during period	63,500,165	64,595,671
Diluted earnings per share		
Adjusted profit attributable to owners of parent (millions of yen)	_	
Increase in number of common shares	1,638	_
(of which, share options)	(-)	(-)
Summary of dilutive shares that are not included in the calculation of diluted earnings per share because they do not have a dilutive effect		_

Significant subsequent events

Not applicable

4. Other

(1) Changes in Officers

To be disclosed when details are concluded.

(2) Other

Purchases and Sales

(i) Sales results by product division

		FY2024 (From June 1, 2024 to May 31, 2025)	
Product division		Amount (millions of yen)	YoY change (%)
Drug Stores			
Medical and health products		119,079	106.6
	OTC	61,867	101.1
	Prescription drug stores	57,211	113.3
Cosmetics		50,107	104.9
Food products		195,835	110.8
Daily products		66,225	106.7
Other		20,832	106.3
Subtotal		452,079	108.2
Supermarkets		2,586	124.5
Nursing Care			
Paid assisted living facilities		720	102.7
Adult day care services		1,513	103.1
Subtotal		2,234	103.0
Revenue from contracts with customers		456,900	108.2
Other revenue (Note)		193	115.3
	Total	457,093	108.2

(Note) Other revenue includes rent income based on the Accounting Standard for Lease Transactions (ASBJ Statement No. 13).

(ii) Sales results by region

Sales results by region for the fiscal year ended May 31, 2025 were as follows:

	FY2023 (From June 1, 2023 to May 31, 2024)		FY2024 (From June 1, 2024 to May 31, 2025)	
	Amount (millions of yen)	Share (%)	Amount (millions of yen)	Share (%)
Kanagawa	258,601	61.2	277,843	60.8
Tokyo	59,593	14.1	63,197	13.8
Shizuoka	45,988	10.9	48,799	10.7
Chiba	36,540	8.7	42,486	9.3
Other	21,605	5.1	24,766	5.4
Total	422,330	100.0	457,093	100.0

(iii) Purchase results

Purchase results by product division for the fiscal year ended May 31, 2025 were as follows:

Product division		FY2024 (From June 1, 2024 to May 31, 2025)	
		Amount (millions of yen)	YoY change (%)
Drug Stores			
Medical and health products		70,887	106.6
	OTC	35,722	101.0
	Prescription drug stores	35,164	113.1
Cosmetics		32,247	105.0
Food products		169,978	110.6
Daily products		47,885	104.5
Other		16,434	106.2
Subtotal		337,433	108.1
Supermarkets		1,996	127.9
Nursing Care			
Paid assisted living facilities		_	_
Adult day care services		_	_
Subtotal		_	_
Purchases for revenue from contracts with customers		339,429	108.2
Other purchases			
	Total	339,429	108.2